Status: Not yet recruiting
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Participants needed: 6,680
Trial details
Phase: Phase 3Age: 18-59Biological sex: AllType: InterventionalSponsor: Changchun BCHT Biotechnology Co.Updated: Aug 21, 2025
Eligibility criteria
Healthy participants aged 18-59 years [+2]
Axillary temperature >37.0°C on enrollment day * [+17]